Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

An epilepsy drug tested for Alzheimer's didn't hit its main goal. A phase 2a crossover trial found that neither low-dose nor high-dose levetiracetam significantly improved global cognition in early Alzheimer's disease compared to placebo. But researchers aren't calling it a failure — subgroup signals suggest the right patients, identified by brain excitability biomarkers, may still benefit.
An epilepsy drug tested for Alzheimer's didn't hit its main goal — but researchers see a path forward. A phase 2a crossover trial presented at the 2026 CTAD conference found that neither low-dose (125 mg BID) nor high-dose (500 mg BID) levetiracetam (LEV) significantly improved global cognition in adults with early Alzheimer's disease compared to placebo. The trial enrolled 43 participants, with 31 randomized and 23 completing all three treatment periods — enrollment fell short of its target due to COVID-19 disruptions.
The rationale for testing LEV in Alzheimer's stems from the discovery that subclinical epileptiform activity — abnormal brain electrical discharges — is more common in AD than previously thought and linked to faster cognitive decline. Rather than calling the results negative, the authors described them as inconclusive, noting that low-dose LEV showed a numerical trend favoring memory improvement, and that treatment effects varied meaningfully by cortical excitability and disease severity.
Key Takeaways:
Why it matters: These findings add to a growing body of evidence suggesting that levetiracetam may benefit a specific subset of Alzheimer's patients — particularly those with high cortical excitability — rather than a broad population. The authors are calling for a larger, adequately powered trial that stratifies participants by baseline brain excitability to definitively test this hypothesis.